Lipo-PEG-PEI complex as an intracellular transporter for protein therapeutics

Background Protein or peptide drugs are emerging therapeutics for treating human diseases. However, current protein drugs are typically limited to acting on extracellular/cell membrane components associated with the diseases, while intracellular delivery of recombinant proteins replaces or replenishes faulty/missing proteins and remains inadequate. In this study, we developed a convenient and efficient intracellular protein delivery vehicle. Materials and methods A cationic liposomal polyethylenimine and polyethylene glycol complex (LPPC) was developed to noncovalently capture proteins for protein transfer into cells via endocytosis. β-glucuronidase (βG) was used in vitro and in vivo as a model enzyme to demonstrate the enzymatic activity of the intracellular transport of a protein. Results The endocytosed protein/LPPC complexes escaped from lysosomes, and the bound protein dissociated from LPPC in the cytosol. The enzymatic activity of βG was well preserved after intracellular delivery in vitro and in vivo. Conclusion Using LPPC as an intracellular protein transporter for protein therapeutics, we illustrated that LPPC may be an effective and convenient tool for studying diseases and developing therapeutics.

[1]  M. Grinstaff,et al.  Polymer–drug conjugate therapeutics: advances, insights and prospects , 2018, Nature Reviews Drug Discovery.

[2]  L. Chang,et al.  Transdifferentiating Astrocytes Into Neurons Using ASCL1 Functionalized With a Novel Intracellular Protein Delivery Technology , 2018, Front. Bioeng. Biotechnol..

[3]  Zicai Liang,et al.  The pH-Triggered Triblock Nanocarrier Enabled Highly Efficient siRNA Delivery for Cancer Therapy , 2017, Theranostics.

[4]  A. Gautam,et al.  THPdb: Database of FDA-approved peptide and protein therapeutics , 2017, PloS one.

[5]  Hafiz M.N. Iqbal,et al.  Protein and Peptide Biopharmaceuticals: An Overview. , 2017, Protein and peptide letters.

[6]  P. Stärkel,et al.  Ras in digestive oncology: from molecular biology to clinical implications , 2014, Current opinion in oncology.

[7]  T. Dingermann,et al.  PEGylation--a well-proven strategy for the improvement of recombinant drugs. , 2014, Die Pharmazie.

[8]  Ken Kato,et al.  Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer , 2014, BMC Research Notes.

[9]  J. Engbersen,et al.  Bioresponsive poly(amidoamine)s designed for intracellular protein delivery. , 2013, Acta biomaterialia.

[10]  Chia-Hung Chen,et al.  A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[11]  Chia-Hung Chen,et al.  Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch , 2012, International journal of nanomedicine.

[12]  Stephen H. Hughes,et al.  Protein delivery using engineered virus-like particles , 2011, Proceedings of the National Academy of Sciences.

[13]  E. Wartchow,et al.  Glycogen Storage Diseases: A Brief Review and Update on Clinical Features, Genetic Abnormalities, Pathologic Features, and Treatment , 2011, Ultrastructural pathology.

[14]  Fu-Rong Chen,et al.  A unique and potent protein binding nature of liposome containing polyethylenimine and polyethylene Glycol: A nondisplaceable property , 2011, Biotechnology and bioengineering.

[15]  L. Lévy,et al.  Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation , 2009, International journal of nanomedicine.

[16]  Hong Yuan,et al.  Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles. , 2009, Colloids and surfaces. B, Biointerfaces.

[17]  Athena W Wong,et al.  DNA Internalized via Caveolae Requires Microtubule-dependent, Rab7-independent Transport to the Late Endocytic Pathway for Delivery to the Nucleus* , 2007, Journal of Biological Chemistry.

[18]  Swarnlata Saraf,et al.  Nanocarriers: promising vehicle for bioactive drugs. , 2006, Biological & pharmaceutical bulletin.

[19]  P. Caliceti,et al.  Nanotechnologies in protein delivery. , 2006, Journal of nanoscience and nanotechnology.

[20]  L. Brown.  Commercial challenges of protein drug delivery , 2005, Expert opinion on drug delivery.

[21]  Jinbao Xu,et al.  PEGylation Confers Greatly Extended Half-Life and Attenuated Immunogenicity to Recombinant Methioninase in Primates , 2004, Cancer Research.

[22]  A. Klibanov,et al.  Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[24]  Scharrer,et al.  Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  Scott D. Putney,et al.  Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.

[26]  I. Wróbel,et al.  Fusion of cationic liposomes with mammalian cells occurs after endocytosis. , 1995, Biochimica et biophysica acta.

[27]  J. Arnout,et al.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993, Blood.

[28]  S Moein Moghimi,et al.  The possible "proton sponge " effect of polyethylenimine (PEI) does not include change in lysosomal pH. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  J. Engbersen,et al.  Bioreducible poly(amidoamine)s as carriers for intracellular protein delivery to intestinal cells. , 2012, Biomaterials.

[30]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[31]  I. Mahmood,et al.  Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins , 2005, Clinical pharmacokinetics.

[32]  R. Schiffmann,et al.  Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources , 1995, Annals of Internal Medicine.